A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors

Antonio Russo, Giuseppe Badalamenti, Chiara Maria Grana, Nicola Fazio, Roberto Gasparri, Edoardo Botteri, Francesca Spada, Antonio Ungaro, Filippo De Marinis, Eleonora Pisa, Nicole Romentz, Spaggiari Spaggiari, Marta Peri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. Results: With a median follow-up of 53 [9-215] months, 61 patients with metachronous and 47 with synchronous metastases were analysed. The most common tool of first recurrence detection was computed tomography. Liver (67%), lymph node (25%), bone (22%) and lung (16%) were the most common sites of relapse. Median time to recurrence was 5 years. Median overall survival (OS) was 72 months for the whole population, with no significant difference between patients with synchronous and metachronous metastases. Age, bone metastases, liver metastases and Ki-67 as a continuous variable all significantly correlated with prognosis at the multivariate analysis. Conclusions: This is one of the largest, single-centre, series of metastatic bpNETs. Among patients with metachronous metastases the pattern of recurrences was heterogeneous as were the follow-up exams used to detect them. The results of our analysis may represent solid bases for designing prospective clinical trials in homogeneous settings of bpNETs.
Original languageEnglish
Pages (from-to)3928-3939
Number of pages12
JournalJournal of Thoracic Disease
Volume10
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. / Russo, Antonio; Badalamenti, Giuseppe; Grana, Chiara Maria; Fazio, Nicola; Gasparri, Roberto; Botteri, Edoardo; Spada, Francesca; Ungaro, Antonio; Marinis, Filippo De; Pisa, Eleonora; Romentz, Nicole; Spaggiari, Spaggiari; Peri, Marta.

In: Journal of Thoracic Disease, Vol. 10, 2018, p. 3928-3939.

Research output: Contribution to journalArticle

Russo, A, Badalamenti, G, Grana, CM, Fazio, N, Gasparri, R, Botteri, E, Spada, F, Ungaro, A, Marinis, FD, Pisa, E, Romentz, N, Spaggiari, S & Peri, M 2018, 'A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors', Journal of Thoracic Disease, vol. 10, pp. 3928-3939.
Russo, Antonio ; Badalamenti, Giuseppe ; Grana, Chiara Maria ; Fazio, Nicola ; Gasparri, Roberto ; Botteri, Edoardo ; Spada, Francesca ; Ungaro, Antonio ; Marinis, Filippo De ; Pisa, Eleonora ; Romentz, Nicole ; Spaggiari, Spaggiari ; Peri, Marta. / A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. In: Journal of Thoracic Disease. 2018 ; Vol. 10. pp. 3928-3939.
@article{b2de4f103e5e41558b9e0ae8e7f08412,
title = "A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors",
abstract = "Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. Results: With a median follow-up of 53 [9-215] months, 61 patients with metachronous and 47 with synchronous metastases were analysed. The most common tool of first recurrence detection was computed tomography. Liver (67{\%}), lymph node (25{\%}), bone (22{\%}) and lung (16{\%}) were the most common sites of relapse. Median time to recurrence was 5 years. Median overall survival (OS) was 72 months for the whole population, with no significant difference between patients with synchronous and metachronous metastases. Age, bone metastases, liver metastases and Ki-67 as a continuous variable all significantly correlated with prognosis at the multivariate analysis. Conclusions: This is one of the largest, single-centre, series of metastatic bpNETs. Among patients with metachronous metastases the pattern of recurrences was heterogeneous as were the follow-up exams used to detect them. The results of our analysis may represent solid bases for designing prospective clinical trials in homogeneous settings of bpNETs.",
author = "Antonio Russo and Giuseppe Badalamenti and Grana, {Chiara Maria} and Nicola Fazio and Roberto Gasparri and Edoardo Botteri and Francesca Spada and Antonio Ungaro and Marinis, {Filippo De} and Eleonora Pisa and Nicole Romentz and Spaggiari Spaggiari and Marta Peri",
year = "2018",
language = "English",
volume = "10",
pages = "3928--3939",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors

AU - Russo, Antonio

AU - Badalamenti, Giuseppe

AU - Grana, Chiara Maria

AU - Fazio, Nicola

AU - Gasparri, Roberto

AU - Botteri, Edoardo

AU - Spada, Francesca

AU - Ungaro, Antonio

AU - Marinis, Filippo De

AU - Pisa, Eleonora

AU - Romentz, Nicole

AU - Spaggiari, Spaggiari

AU - Peri, Marta

PY - 2018

Y1 - 2018

N2 - Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. Results: With a median follow-up of 53 [9-215] months, 61 patients with metachronous and 47 with synchronous metastases were analysed. The most common tool of first recurrence detection was computed tomography. Liver (67%), lymph node (25%), bone (22%) and lung (16%) were the most common sites of relapse. Median time to recurrence was 5 years. Median overall survival (OS) was 72 months for the whole population, with no significant difference between patients with synchronous and metachronous metastases. Age, bone metastases, liver metastases and Ki-67 as a continuous variable all significantly correlated with prognosis at the multivariate analysis. Conclusions: This is one of the largest, single-centre, series of metastatic bpNETs. Among patients with metachronous metastases the pattern of recurrences was heterogeneous as were the follow-up exams used to detect them. The results of our analysis may represent solid bases for designing prospective clinical trials in homogeneous settings of bpNETs.

AB - Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. Results: With a median follow-up of 53 [9-215] months, 61 patients with metachronous and 47 with synchronous metastases were analysed. The most common tool of first recurrence detection was computed tomography. Liver (67%), lymph node (25%), bone (22%) and lung (16%) were the most common sites of relapse. Median time to recurrence was 5 years. Median overall survival (OS) was 72 months for the whole population, with no significant difference between patients with synchronous and metachronous metastases. Age, bone metastases, liver metastases and Ki-67 as a continuous variable all significantly correlated with prognosis at the multivariate analysis. Conclusions: This is one of the largest, single-centre, series of metastatic bpNETs. Among patients with metachronous metastases the pattern of recurrences was heterogeneous as were the follow-up exams used to detect them. The results of our analysis may represent solid bases for designing prospective clinical trials in homogeneous settings of bpNETs.

UR - http://hdl.handle.net/10447/295518

UR - http://jtd.amegroups.com/article/download/22671/pdf

M3 - Article

VL - 10

SP - 3928

EP - 3939

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

ER -